Entrada - Pangali EV/EBITDA TRDA

The historical share price analysis of Entrada Therapeutics (TRDA) on the GURU.Markets platform shows an EV/EBITDA ratio of 0.00. Entrada Therapeutics (TRDA) relies on a highly specialized protein delivery system to target muscle and nerve pathologies, mitigating high development risks through strategic alliances. Growth is driven by the success of the EEV method in treating Duchenne muscular dystrophy and payments from major pharmaceutical behemoths. This innovative approach enables the creation of medications for patients who previously lacked treatment options.

TRDA (Entrada) riwayat Pangali EV/EBITDA saka 23.11.2025 nganti 12.11.2026

TRDA (entradatx.com): rincian analitis lan laporan miturut indikator

- rega pasar lan target rega analis:

Bagan rega Entrada|TRDA - Prakiraan gabungan firma investasi

- rincian nilai pasar emiten:

Kapitalisasi pasar Entrada Therapeutics, Inc|TRDA - Total Nilai Perusahaan

- statistik nilai buku emiten:

Nilai Akuntansi saben Saham Entrada Therapeutics|TRDA - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku entradatx.com|TRDA - Nilai Agregat Aset

- data utang lan likuiditas:

Utang marang Ekuitas Entrada Therapeutics|TRDA - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Entrada Therapeutics, Inc.|TRDA - Utang perusahaan|Rasio utang marang kapitalisasi buku Entrada Therapeutics, Inc|TRDA - Utang jangka dawa|Utang jangka cendhak perusahaan Entrada Therapeutics|Indikator likuiditas cepet entradatx.com

- indikator pendapatan resik lan kelipatan nilai:

TRDA - Penghasilan resik perusahaan|Proyeksi bathi mangsa ngarep Entrada Therapeutics|TRDA - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep Entrada Therapeutics|TRDA - Rasio P/E diaturake wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Entrada Therapeutics, Inc|TRDA - Bathi perusahaan sadurunge pajak, bunga, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Entrada Therapeutics|TRDA - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan entradatx.com|TRDA - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Entrada Therapeutics

Ringkesan analitik perusahaan:TRDA (Entrada)

Conservative capital demands maximum transparency of capital structure and operational business resilience. The EV/EBITDA multiple assesses the total enterprise value relative to its earnings before interest, taxes, depreciation, and amortization, excluding the impact of debt load. For Entrada Therapeutics (TRDA), amid fierce competition for neurology patents, this metric reveals the real value of assets. By analyzing the fluctuations in the company's EV/EBITDA level, an investor can determine the risk of overpaying for an overheated asset.

Analisis pesaing